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Abstract
Background: The diagnosis of malaria can be difficult in non-endemic areas, such as the United States, and delays
in diagnosis and errors in treatment occur too often.
Methods: A nationwide survey of laboratories in the United States and its nine dependent territories was
conducted in 2010 to determine factors that may contribute to shortcomings in the diagnosis of malaria. This
survey explored the availability of malaria diagnostic tests, techniques used, and reporting practices.
Results: The survey was completed by 201 participants. Ninety percent reported that their laboratories had at least
one type of malaria diagnostic test available on-site. Nearly all of the respondents’ laboratories performed thick and
thin smears on-site; approximately 50% had access to molecular testing; and only 17% had access to rapid
diagnostic tests on-site. Seventy-three percent reported fewer than five confirmed cases of malaria in their
laboratory during the 12-month period preceding the survey. Twenty-eight percent stated that results of species
identification took more than 24 hours to report. Only five of 149 respondents that performed testing 24 hours a
day, 7 days a week complied with all of the Clinical and Laboratory Standards Institute (CLSI) guidelines for analysis
and reporting of results.
Conclusion: Although malaria diagnostic testing services were available to a majority of U.S. laboratories surveyed,
very few were in complete compliance with all of the CLSI guidelines for analysis and reporting of results, and
most respondents reported very few cases of malaria annually. Laboratories’ difficulty in adhering to the rigorous
CLSI guidelines and their personnel’s lack of practice and proficiency may account for delays and errors in
diagnosis. It is recommended that laboratories that infrequently process samples for malaria seek opportunities for
practice and proficiency training annually and take advantage of available resources to assist in species
identification.
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Background
M a l a r i ac o n t i n u e st ob ee n d e m i ci nm o r et h a n1 0 0
countries worldwide, where it remains a leading cause
of morbidity and mortality [1]. Millions of U.S. travellers
venture to endemic countries annually [2]. An average
of 1,500 cases and five deaths due to malaria occur
annually in the U.S. These numbers include U.S.
travellers to endemic countries as well as foreign visitors
diagnosed and treated in the U.S. [3-7]. A total of 19
malaria-related deaths were reported in the U.S.
between 2004 and 2008; diagnostic delay was a contri-
buting factor in at least six [3-7]. Prompt and accurate
diagnosis and timely treatment are crucial in reducing
malaria-associated morbidity and mortality [8].
In a case series of imported malaria in the late 1990s
in Canada, up to 92% of patients who presented to phy-
sicians without expertise in tropical medicine experi-
enced delays in diagnosis due to physician failure to
consider malaria as a diagnosis on initial presentation,
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tion, or administration of incorrect therapy to treat the
parasite(s) identified [9]. In this study, the majority of
community laboratories did not perform malaria smears
on an urgent basis, nor did they routinely report species
identification or percent parasitaemia [9]. Overall, these
laboratories had significant reporting delays, misdiag-
noses and incorrect species identification [9]. Addition-
ally, proficiency testing in the U.S. in the last decade has
revealed especially poor identification of non-falciparum
species of malaria [10]. A decline in number of cases
reported that include species identification has also been
seen in the malaria surveillance data reported to
the Centers for Disease Control and Prevention (CDC)
(Figure 1) [3-7].
The Clinical and Laboratory Standards Institute’s
(CLSI) recommendations for laboratories performing
malaria diagnostic testing include [11]:
1. Make diagnostic testing available 24 hours a day,
seven days a week.
2. Prepare at least three thick and thin smears.
3. Use Giemsa stain for definitive diagnosis. It allows
proper visualization of stippling (Schűffner’s dots) in
Plasmodium vivax and Plasmodium ovale and can
play a crucial role in identification of these species.
Although parasites are visible by Wright’sa n d
Wright-Giemsa stains, these stains do not allow
visualization of stippling.
4. Examine at least 300 fields using the 100× oil
immersion objective.
5. Report microscopy results immediately to the
requesting physician or ward.
6. Examine at least 10 fields on the thin film to
determine percent parasitaemia; many more fields
should be examined for patients from the U.S. who
typically have lower parasitaemia (CDC recommends
counting parasitized red blood cells (RBCs) among
500-2,000 RBCs on the thin smear [12]).
A preliminary report of positive or negative should be
available within four hours; percent parasitaemia should
be reported within six hours and species identification
within 24 hours.
The focus of this survey was to identify laboratory
practices that could contribute to delayed or incorrect
diagnoses. The goal was to determine the proportion of
laboratories in the United States that perform diagnostic
malaria testing using procedures that might contribute
to diagnostic delays.
Methods
A convenience sample of laboratory-related personnel
w a so b t a i n e dt h r o u g han a t i o n w i d es u r v e yo fU . S .
laboratories to determine the practices for malaria diag-
nostic testing, including availability of diagnostic tests,
time required for reporting, and test methodologies
used (see Additional file 1 for survey questions). An
introductory e-mail and two reminder e-mails with an
embedded link to a web-based survey were sent to two
listservs maintained by the American Society for Micro-
biology. The listservs include doctoral level microbiology
laboratory directors and other members of the micro-
biology laboratory including pathologists, haematolo-
gists, clinical laboratory scientists, and medical
technologists worldwide; the survey was limited to indi-
viduals residing in the U.S. and its nine dependent
territories.
The survey was validated by several members of the
laboratory staff at varying education levels including
bachelors, masters and doctorate level personnel. Survey
results were analysed using SurveyMonkey™ and Excel
(Microsoft Office 2007, Seattle WA). This study was
submitted to the Institutional Review Board of Emory
University and deemed exempt from review. Informed
consent was implied by response.
Results
Study participants
A total of 278 participants initiated the survey and 201
(72.3%) completed the survey. Respondents were from
laboratories located in 46 of the 59 (78%) states and ter-
ritories, including 30 respondents in California, 22 in
New York, 14 in Texas, and 12 in Ohio (Figure 2). The
majority of respondents were microbiologists or micro-
biology laboratory directors or supervisors; the remain-
der were haematologists, pathologists, clinical laboratory
scientists and medical technologists. Nearly half of
respondents described their facility as a community
Figure 1 Malaria cases by species, 1985-2009. The percentage of
cases reported as unknown species has increased considerably in
recent years.
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Page 2 of 10hospital-affiliated laboratory, and fewer than one-third
were affiliated with a university hospital (Table 1).
Availability of diagnostic testing
Ninety percent of all respondents worked in a laboratory
with at least one type of malaria diagnostic test available
on-site. This included all respondents from university
hospital laboratories, 87% from community hospital-
affiliated laboratories, 90% from commercial referral
laboratories, and 88% from other laboratories (Table 1).
The remaining 10% sent all specimens to an outside
laboratory for analysis.
Laboratories with on-site malaria diagnostics
Of the respondents who reported that their laboratory
performed diagnostic testing for malaria, 149 (85%)
reported that their laboratory provided diagnostic testing
either in-house or via on-call personnel, 24 hours a day,
s e v e nd a y saw e e k .T h i sn u m b e ri n c l u d e d9 6 %o f
respondents from university hospital laboratories, 83%
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Figure 2 Number of respondents from each U.S. state or dependent territory.
Table 1 Classification of laboratories
Laboratory Classification No. (%)
a Percentage of laboratory type with on-site testing available (%)
Community hospital 130 (46.8) 87
University hospital 83 (29.8) 100
Commercial referral laboratory 21 (7.6) 90
Public health 15 (5.4) 67
VA hospital 9 (3.2) 89
Primary care center 4 (1.4) 75
Other 16 (5.8) 88
TOTAL 278
a Includes all respondents that started survey, regardless of completion status.
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Page 3 of 10from commercial referral laboratories, 82% from com-
munity hospitals, and 100% from other laboratories. The
remaining 15% worked in laboratories with personnel
who could perform diagnostic testing only during the 8-
to 12-hour work day.
Sixty-nine respondents (32%) noted that their labora-
tory received <10 specimens for malaria diagnostic test-
ing within the 12 months preceding the survey. Twenty-
seven (13%) received a large volume, with >100 speci-
mens sent for analysis; however, most of these speci-
mens were negative. Only 10 (~5%) had >15 confirmed
cases, while 158 (73%) respondents noted that their
laboratory had five or fewer confirmed cases of malaria
during the 12 months preceding the survey. The type of
diagnostic testing available on-site is shown in Figure 3.
Nearly all laboratories with on-site testing performed
both thick and thin smear analysis by light microscopy.
Only 35 respondents (17%) reported using rapid diag-
nostic testing (RDT); 20 of these were from university
hospital laboratories, seven from community hospitals,
two from commercial referral laboratories, one from a
public health laboratory, and five from other labora-
tories. PCR was available to about half the respondents,
with nine respondents reporting direct access in their
laboratory (two university-affiliated laboratories, two
commercial referral laboratories, three public health
laboratories, and two other laboratories) and an addi-
tional 91 respondents with access to PCR as a send-out
test.
Technique
Of the 202 respondents in laboratories where light
microscopy was performed on-site, nearly half (47%)
used Giemsa stain in at least one step of the analysis of
thick and thin smears; several others used more than
one of three staining techniques: Giemsa, Wright-
Giemsa, and Wright stain. Two respondents reported
using acridine orange stain; in one laboratory, this was
t h eo n l ys t a i nu s e d ,a n di nt h eo t h e r ,p o s i t i v es t a i n i n g
with acridine orange was followed by Wright-Giemsa
staining.
Eighty-three respondents (46%) reported that their
laboratory reviewed ≥three slides from a single patient’s
sample before a specimen was considered negative; this
was true for 44% of university and 53% of community
hospital respondents. A minority, 16 (~9%), reported
that their laboratory reviewed only one slide to deter-
mine a negative test. The majority of respondents, 112
(63%), reported that their laboratory reviewed ≥300 high
power fields (HPF) prior to determining that a slide was
negative. This was the case in 75% of respondents from
commercial referral laboratories, 68% from university
hospitals, and 67% from other laboratories; 12 (~7%)
reviewed <100 HPF to come to this conclusion.
The majority of respondents, 91 (58%), reported that
500-2,000 RBCs were counted to determine percent
parasitaemia. This included 67% of respondents from
public health laboratories, 60% from university hospital
laboratories, and 71% from other laboratories. Fourteen
Figure 3 Availability of Malaria Diagnostic Testing at Laboratories with On-Site Testing. This graph shows the percentage of tests
performed on-site and as send-outs at laboratories with at least one malaria diagnostic test available on-site (N = 203). (ELISA- Enzyme-linked
immunosorbent assay, IFA- indirect fluorescent antibody, PCR- polymerase chain reaction).
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counting >2,000 cells, while 14% reported counting
<500 cells.
Reporting
The majority of respondents, 115 (64%), noted that a
preliminary result was reported within 4 hours of receiv-
ing the specimen. This was the case for 74% of respon-
dents from university hospitals, 71% from public health
laboratories, and 62% from community hospitals.
Approximately seven in 10 respondents (126) reported
that at least two personnel (in most laboratories, two
technologists) reviewed a slide prior to reporting a nega-
tive result; the remaining respondents reported that only
a single technologist reviewed the slide. In contrast,
most respondents, 127 (71%), reported that positive
results were confirmed by a pathologist or laboratory
director/supervisor. A little over half of the respondents,
93 (52%), noted that their laboratory reported percent
parasitaemia within six hours. A majority of respondents
from university (59%) and public health (71%) facilities
stated that percent parasitaemia was reported within
this time period.
A species-specific diagnosis was possible in-house for
144 (89%) respondents. For 133 (70%) respondents, a
species-specific diagnosis was made within 24 hours;
half of these were made within 6 hours after receipt of
specimen. Species identification was available within 6
hours according to 67% of respondents from public
health laboratories, 40% from university hospitals, 29%
from community hospitals, and 57% from other
laboratories. Twenty-eight percent reported that a spe-
cies diagnosis took >24 hours.
In 102 (63%) respondents’ laboratories, species identi-
fication was performed in-house by either a microbiol-
ogy director/supervisor or a pathologist. Approximately
40% noted that species identification was performed in-
house and subsequently confirmed at an outside labora-
tory, such as the state or local health department or
CDC. Eleven percent reported that species identification
was done only at an outside laboratory.
Compliance summary
Of the 149 respondents who reported that their labora-
tory provided diagnostic testing either in-house or via
on-call personnel, 24 hours a day, seven days a week,
using the strict definition of immediate preliminary
reporting within four hours, percent parasitaemia
within six hours and species identification within 24
h o u r so n l yf i v ew e r ei nc o m p l e t ec o m p l i a n c ew i t ha l l
six CLSI guidelines (Figure 4). This included three
respondents’ laboratories affiliated with a university
hospital, one from a community hospital, and one
from a laboratory categorized as other. If more liberal
definitions were used to define immediate reporting
(ie: preliminary report within12 hours, percent parasi-
taemia within 12 hours, and species identification
within 36 hours) nine respondents’ laboratories were
in complete compliance (four from university hospitals,
three from community hospitals, one from a commer-
cial referral laboratory, and one from a laboratory cate-
gorized as other).
Figure 4 Sequential Compliance with CLSI Guidelines.
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Twenty-eight (10%) respondents reported that their labora-
tory provided only send-out diagnostic testing for malaria.
Seventeen (60%) were affiliated with community hospitals,
five (18%) with public health laboratories, and two each
with commercial referral and other laboratories. Of the 27
respondents whose laboratories offered only send-out test-
ing for malaria who completed the survey, 85% reported
receiving <10 specimens for malaria diagnostic testing
within the 12 months preceding the survey. Only one
respondent stated his laboratory received >100 specimens.
Twenty-five (93%) reported ≤five confirmed cases of
malaria; half of these respondents had seen no positive
cases of malaria in their laboratory in the past year.
The diagnostic tests available to the laboratories where
only off-site testing is performed are shown in Figure 5.
The majority reported that their laboratory had access
to thick and thin smears by light microscopy (71%), and
some reported access to PCR (43%). Many of these
respondents (41%) reported that their laboratories
received a report of the level of parasitaemia and specia-
tion within 24 - 48 hours; three respondents reported
that results were not available until >7 days after the
specimen had been sent out.
Discussion
It is undeniable that there are significant challenges in
diagnosing malaria, especially in areas where it is not
endemic. Laboratory challenges in the diagnosis of
malaria include patients’ low parasite density, altered
parasite morphology due to the patients’ use of chemo-
prophylaxis, empiric therapy, mishandling of specimens,
and inexperience in identifying malaria parasites due to
the small number of cases seen [8]. The combination of
these factors potentially reduces the sensitivity of micro-
scopy significantly, making diagnosis very difficult [8].
A recent retrospective review by Edson et al analysing
the proficiency of U.S. laboratories to identify malaria
parasites reported a failure rate of 11.2% for identifica-
tion of Plasmodium falciparum [10]. Although this
means that more than one in 10 specimens were not
correctly identified, it is encouraging compared with
Canadian and British laboratory failure rates of 27% and
21% respectively [13,14]. However, given the potential
for significant morbidity and mortality associated with
delayed or incorrect diagnosis of P. falciparum,
improvement is needed.
In this study, the majority of laboratories surveyed
reported using both thick and thin smears; very few
respondents reported the use of thin smears alone,
an inferior technique. It is i m p o r t a n tt h a tb o t ht h i c k
and thin smears be evaluated in the examination of
blood specimens for malaria. Thick smears are useful
for detecting parasites, while thin smears are useful
for species identification and quantification of
parasites.
Figure 5 Availability of Malaria Diagnostic Testing at Laboratories without On-Site Testing. This graph shows the percentage of
respondents from laboratories where all malaria testing is performed off-site reporting access to various tests (N = 28). (ELISA- Enzyme-linked
immunosorbent assay, IFA- indirect fluorescent antibody, PCR- polymerase chain reaction).
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was available only during the eight- to twelve-hour work
day with no access to on-call personnel during the off-
hours. Malaria is a potentially life threatening disease:
therefore, it is recommended that all blood films be read
immediately. CLSI recommends that ‘any laboratory
providing the expertise to identify malarial parasites
should do so on a 24-hour basis, seven days a week’
[11]. Therefore qualified personnel who can perform
this testing should be on-call during off-hours.
Very few respondents reported availability of serologic
testing in their laboratories; several other respondents
reported its availability as a send-out test. Serologic test-
ing is used only for retrospective diagnosis of past
malaria infection [15] and is not recommended for diag-
nosis of acute infection. Anti-malarial antibodies are
produced one to two weeks after initial infection and
persist for three to six months after parasite clearance.
Malaria RDTs are being used more frequently over the
last several years, primarily in malaria-endemic areas
[16]. Microscopy remains the gold standard, and in the
U.S. is the primary and in some cases the only diagnos-
tic tool used; as evidenced by the small number of
respondents who reported having access to RDTs in
their laboratories. RDTs can be beneficial in laboratories
lacking personnel proficient in the microscopic diagnosis
of malaria, as they allow for a rapid diagnosis of malaria,
which can then be confirmed by microscopy or PCR.
RDTs utilize immunochromatographic methods to
detect malarial antigens present in peripheral blood to
provide a quick result as to whether or not a patient is
infected with malaria. Certain RDTs are able to give
limited information about species (i.e. to indicate that at
least P. falciparum is present) but none are able to pro-
vide quantification of parasitaemia. There are many
brands and types of RDTs worldwide, but only one is
FDA-approved for diagnostic use in the U.S.: Binax-
NOW Malaria
® (Inverness Medical, Princeton, NJ). This
test targets both the histidine-rich protein II (HRPII)
antigen specific to P. falciparum and a malarial aldolase
common to all human malaria species; it is therefore
able to provide a diagnosis of malaria as well as deter-
mine specifically if P. falciparum is present[17]. How-
ever, all results must be confirmed by microscopy under
the product’s current FDA approval.
The detection of parasites in non-immune individuals
who may be symptomatic at very low parasite densities
is an additional barrier; unless enough fields are
counted, these specimens may be mistakenly read as
negative. In such cases it is imperative that repeat blood
smears be performed. Standard guidelines recommend
that a total of three specimens be obtained before
declaring a patient does not have malaria. It is impor-
tant to note that ensuring that an adequate number of
specimens are sent is the responsibility of the physician;
however, the laboratory may assist the physician with a
reminder that three specimens must be sent to guaran-
tee an accurate result.
Any laboratory with the capacity to perform a com-
plete blood count with manual differential has the tools
necessary to make a diagnosis of malaria and to report
the percent parasitaemia (Additional file 2). All haema-
tology technicians should have the basic training to
identify a parasite on peripheral blood smear. Parasite
speciation requires additional training and may therefore
require sending the specimen to a reference laboratory.
CDC provides diagnostic assistance, most rapidly (within
12-24 hours) through telediagnosis, where digital photo-
graphs and basic epidemiological data are sent to on-
call personnel (See Additional file 2 for contact informa-
tion*). Additionally, online diagnostic instructions are
available at CDC’s parasitology diagnostic website,
DPDx [18] (See references for website address). For
laboratories without on-site malaria diagnostic testing,
consideration should be given to implementing RDTs,
with confirmation via off-site testing.
Accurate identification of the infecting species has sig-
nificant implications for treatment, as patients with P.
vivax and P. ovale infections require therapy with pri-
maquine to prevent relapses from latent hypnozoites in
the liver. Accurate species identification is also impor-
tant for detecting changes in the epidemiology of
malaria among travellers. Laboratories should ensure
that a definitive species-level diagnosis is made; PCR is
a useful tool for definitively determining the Plasmo-
dium species present. In addition, use of PCR should
minimize the number of false negative and false positive
results. PCR is more sensitive than microscopy for
detecting mixed infections [19,20], as these are easily
missed on a blood smear if morphologic features of
both species are not visualized.
Although a high percentage of respondents reported
compliance with each individual CLSI guideline, only
very few representatives surveyed reported compliance
with all CLSI guidelines. The purpose of these guide-
lines is to standardize practices across laboratories, as
well as to recommend practices which will ultimately
lead to the best outcomes through rapid identification
and reporting of positive malaria smears. While species
identification is critical to ensure that appropriate defi-
nitive treatment is given, providing a rapid presump-
tive diagnosis of malaria is most important to ensure
prompt treatment is given. Therefore, while ideally all
CLSI guidelines should be adhered to, those aimed at
improving the rapidity and accuracy of initial report-
ing, such as counting an adequate number of fields
and an adequate number of smears, are the most
important.
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Page 7 of 10Figure 6 outlines a useful algorithm for laboratories
receiving specimens for malaria diagnostic testing. A
preliminary report of positive or negative should be
available within 4 hours; percent parasitaemia should be
reported within 6 hours and species identification within
24 hours. This may be more difficult in laboratories
where tests are sent out; laboratory supervisors should
facilitate rapid retrieval of these results to ensure
Yes
Specimen sent to lab for 
malaria diagnostic testing
Are expert personnel  
available on-site?
No
(+ Test) (- Test)
-Perform thick and thin smears
-Report results to ordering physician within 4 hours of receiving specimen 
-If parasites present determine percent parasitemia and species identification 
Are there on-call expert 
personnel?
No Yes
Use rapid diagnostic test
Initiate presumptive 
therapy
Notify on-call 
personnel STAT!
If species diagnosis unclear, send specimen to reference laboratory for further testing
-If parasites present, physician to initiate therapy while awaiting percent parasitemia 
and species identification
-If no parasites present, repeat for a total of 3 sets of smears
Figure 6 Recommended Malaria Diagnostic Testing Algorithm.
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manage the patient. Otherwise, they should consider
making RDTs available to facilitate the initial diagnosis.
If this is not possible, specimens should be referred to a
laboratory where malaria diagnostic testing can be per-
formed in a timely fashion. Patient care is a collabora-
tive effort which includes many members of the medical
team. In addition to the vital role of the laboratory staff,
it is paramount for physicians to obtain a complete his-
tory, including travel history, and keep malaria high on
the differential diagnosis of patients presenting with
fever. As physicians it is our responsibility to ascertain
the availability of diagnostic tests in our institution’s
laboratories and, if they are lacking, advocate for more
timely access to better malaria testing.
Limitations
This survey was sent out to two listservs maintained by
the American Society for Microbiology. As there is over-
lap in the membership of these lists and not all people
on the list were eligible for participation (e.g. interna-
tional members), it is impossible to calculate the true
response rate, and our results may not be reflective of
practices at all laboratories across the U.S. As with any
survey, there is the potential for respondent bias.
Although the responses received were from multiple dif-
ferent types of laboratories in a wide geographic distri-
bution, it is possible that laboratories with more
sophisticated testing for malaria or those who receive
more samples for malaria may have been more likely to
respond. Therefore, this data may represent the best
case scenario rather than what occurs at the majority of
laboratories.
The names of laboratories and affiliated institutions
were not obtained; this was intentionally done in order
to maintain the confidentiality of the respondents. How-
ever, this poses a limitation, as more than one member
of a laboratory may have submitted answers to the sur-
vey. It is for this reason that the results are reported
based on the number of respondents rather than the
number of laboratories.
Conclusions
The results of this survey attest to the availability of ser-
vices for malaria diagnostic testing in U.S. laboratories,
showing that the delays and accuracy of diagnosis may
be due to lack of practice and proficiency as well as the
difficulty in complying with the rigorous guidelines set
by the CLSI. Even in laboratories with large volumes of
samples processed for malaria parasite detection, each
individual staff member likely sees very few cases per
year; consequently, it is imperative that all laboratories,
especially those that infrequently process samples for
malaria seek opportunities for practice and proficiency
training annually (Additional file 3).
Additional material
Additional file 1: Malaria Diagnostic Survey Questionnaire.
Additional file 2: Microscopic Procedures for Diagnosing Malaria.
Additional file 3: Select Opportunities for Practice and Additional
Training for Laboratory Diagnosis of Blood and Tissue Parasites.
List of abbreviations used (in alphabetical order)
CDC: Centers for Disease Control and Prevention; CLSI: Clinical and
Laboratory Standards Institute; DPDx: Division of Parasitic Disease Diagnosis;
ELISA: Enzyme-linked immunosorbent assay; FDA: Food and Drug
Administration; HPF: high power fields; HRP II: histidine-rich protein-2; IFA-
indirect fluorescent antibody; PCR: polymerase chain reaction; RBCs: red
blood cells; RDT: rapid diagnostic test.
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